Compare L3Harris Technologies Inc (LHX) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Health Care Select Sector SPDR Fund — how do they compare? L3Harris Technologies Inc trades at $285.15 (market cap $51.74B), while Health Care Select Sector SPDR Fund trades at $159.56. The key difference: L3Harris Technologies Inc pays a 1.8% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, L3Harris Technologies Inc nearer its low. Which is the better fit depends on your goals.
| LHX | XLV | |
|---|---|---|
Market Cap | $51.74B | — |
Sector | Industrials | — |
52-Week High | $378.48 | $164.48 |
52-Week Low | $264.42 | $129.01 |
Enterprise Value | $62.50B | — |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $277.71, down 1.52% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $2.72 exceeding the $2.53 expectation. Recent contract wins, including a U.S. Space Force satellite award and U.S. Army communication system orders, highlight ongoing defense sector strength. The stock's valuation includes a P/E of 30.46 and a net income margin of 7.71% for 2025.
The outlook for LHX is positive, supported by a robust $40.7 billion backlog and 75% analyst buy ratings with a $367.50 consensus price target, implying significant upside. Key risks include execution on major contracts, defense budget fluctuations, and competitive pressures. The recent dividend of $1.25 per share underscores financial health, but investors should monitor debt levels and geopolitical factors affecting defense spending.
XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.
XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
